TMEM139: A Transmembrane Protein with Potential as a Drug Target or Biomarker

Target Name: TMEM139

NCBI ID: G135932

TMEM139

Other Name(s): Transmembrane protein 139, transcript variant 1 | transmembrane protein 139 | TMEM139 variant 1 | TM139_HUMAN | Transmembrane protein 139

TMEM139: A Transmembrane Protein with Potential as a Drug Target or Biomarker

TMEM139 is a member of the transmembrane protein (TMEM) family, which plays a significant role in various cellular processes, including cell signaling, neurotransmission, and intracellular routing of various signaling pathways. TMEM139 is expressed in various tissues and cells, including brain, heart, kidney, and pancreas, making it a potential drug target or biomarker. This article will provide an overview of TMEM139, its expression pattern, potential drug targets, and its potential as a biomarker in various diseases.

Expression and Localization

TMEM139 is a 21-kDa protein that consists of an N-terminal cytoplasmic domain, a transmembrane region, and an C-terminal cytoplasmic domain. TMEM139 is predominantly expressed in the brain, with higher levels of expression observed in the prefrontal cortex, hippocampus, and cerebellum. TMEM139 is also expressed in other tissues, including heart, kidney, and pancreas, but with lower levels of expression.

TMEM139 is predominantly localized to the endoplasmic reticulum (ER) and endosomal system, which is a complex system for the delivery and processing of proteins. TMEM139 is involved in the delivery of various proteins to the ER and is a key component of the endosomal system. The ER-associated degradation (ERAD) pathway is a well-established mechanism for the degradation of misfolded or unprocessed proteins, and TMEM139 is involved in this process by promoting the loading of target proteins onto endosomes.

Potential Drug Targets

TMEM139 is a protein that has potential as a drug target due to its involvement in various cellular processes. One of the potential drug targets for TMEM139 is the regulation of mitochondrial dynamics, which is a critical process for the function of many cellular processes, including energy metabolism. TMEM139 has been shown to regulate the mitochondrial dynamics in various cellular models, including cancer cells (8) and neuroprosthetics.

Another potential drug target for TMEM139 is the regulation of the endosomal system, which is involved in the delivery of various proteins to the ER and play a role in the regulation of protein quality and quantity. TMEM139 is involved in the ER-associated degradation (ERAD) pathway, which is a well-established mechanism for the degradation of misfolded or unprocessed proteins. Therefore, inhibitors of ERAD or TMEM139 could potentially lead to the accumulation of misfolded or unprocessed proteins, including those that are associated with various diseases, such as neurodegenerative disorders.

TMEM139 has also been shown to be involved in the regulation of cell signaling pathways, including the regulation of ion channels (13) and protein tyrosination. Therefore, inhibitors of TMEM139 could potentially lead to the disruption of these signaling pathways, which could have implications for various cellular processes, including cell growth, survival, and angiogenesis.

Potential Biomarkers

TMEM139 may also be used as a biomarker for various diseases. One of the potential biomarkers for TMEM139 is its expression level, which can be used as a marker for various diseases, including neurodegenerative disorders. Another potential biomarker for TMEM139 is its involvement in the regulation of cellular processes, including the regulation of mitochondrial dynamics.

TMEM139 has also been shown to be involved in the regulation of the endosomal system, which is involved in

Protein Name: Transmembrane Protein 139

Functions: May be involved in cellular trafficking of proteins such as SLC4A1

The "TMEM139 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM139 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets